Introduction
Simvastatin is one of the most potent inhibitors of cholesterol synthesis both in vitro and in vivo that competitively suppress 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme for the mevalonate pathway (1) . Besides regulating cholesterol synthesis, HMG-CoA reductase plays an important role in cell proliferation as the mevalonate pathway yields both cholesterol and non-sterol metabolites (such as geranylaeraniol and farnesol) which are essential for the DNA replication (2) . Pharmacological approaches have shown that simvastatin inhibits proliferation of rat smooth muscle cells (SMC) (3) .
Atherosclerosis is characterized not only by the enhanced proliferation of SMC but also that of endothelial cells (EC) (4, 5) . The enhanced SMC proliferation is important in the development of atherosclerosis while that of EC is essentially required for the repair in this pathological condition (4, 6) .
We have recently shown that simvastatin decreases the intracellular free cholesterol level of cultured bovine EC (7), the reduction of which was accompanied by the enhancement of the cell membrane fluidity (8) . To extend these observation and to further investigate the effects of simvastatin on atherosclerotic pathogenesis, we studied the effect of simvastatin on the proliferation of EC compared to that of SMC.
Materials and Methods

Preparation of chemicals
The following chemicals were used : Simvastatin (produced by Merk-Banyu Co., Ltd., Tokyo, Japan) was a generous gift of Sankyo Co., Ltd. (Tokyo, Japan 
